MSBIO, Inc.

₩6,380As of Sun 8 Nov 2026, 12:00 UTC

KOSDAQ:0013Y0Healthcare

Country South Korea

PE (Fwd) 13.66

TSR 10Y CAGR —

Div yield —

ROE 29.01%

Medical Instruments & Supplies

Beta (5Y) —

PE TTM 17.29

TSR TTM —

Mkt cap ₩173.6B

ROIC 62.03%

SE Grade™

Value

Quality

Moat

1Y Price

Reference

₩6,804

6.65%

(17.60%)

Price above Reference Value

TTM

FYE 31 Dec KRW

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

23.79

Revenue₩B

—

14.82

17.97

23.79

27.37

26.68%

—

32.35

Revenue growth%

—

21.25

32.35

15.04

26.80

—

66.36

Gross margin%

—

60.91

64.88

66.36

67.10

64.88

—

35.98

Operating margin%

—

31.54

33.33

35.98

37.30

33.33

—

30.64

Net margin%

—

28.85

29.60

30.64

31.16

29.60

—

17.29

P/E ratio (avg)x

—

14.78

—

18.23

EV/EBITx

—

9.763

—

5.25

FCF yield (avg)%

—

6.96

—

27.82

FCF margin%

—

(6.23)

19.38

27.82

32.04

19.38

—

0.908

FCF / Net incomex

—

(0.216)

0.655

0.908

1.028

0.655

—

62.03

ROIC%

—

30.48

38.00

62.03

90.43

38.00

—

29.01

Return on equity%

—

26.81

28.60

29.01

25.64

28.60

—

12.93

Return on assets%

—

21.99

22.41

12.93

13.14

21.99

—

369.00

EPS₩

—

1,109

274.00

369.00

431.70

(42.32%)

—

34.67

EPS growth%

—

(75.29)

34.67

16.99

(20.31)

—

1,468

Bookvalue per sh₩

—

4,136

1,094

1,468

1,900

(40.42%)

—

335.04

FCF per share₩

—

(239.37)

179.41

335.04

443.90

86.75%

—

Dividend per sh₩

—

Div yield (avg)%

—

Payout ratio%

—

27.20

Shares (diluted)M

—

3.856

19.42

19.75

◌19.75

126.30%

—

(1.72)

Buyback yield%

—

(403.45)

(1.72)

◌—

(202.59)

—

D/E ratiox

—

0.142

0.027

—

0.027

—

156.0

Enterprise value₩B

—

99.65

—

LT debt₩B

—

2.135

0.405

—

(81.03%)

—

Peers (US$128.4M)

Cap (US$)

Boditech Med Inc.

142.4M

7.418x

Bio Plus Co., Ltd

133.2M

18.78x

Sky Labs Inc.

110.5M

—

MaxCyte, Inc.

130.0M

—

Capital

TTM

10Y

Leveragex

(1.946)

(0.780)

EBIT/Intx

—

863.1

Own earn%

—

Sh yield%

(1.72)

(202.59)

Owners

Insiders/Inst%

40.55

4.98

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

3/3

Revenue growth years

—

EPS growth years

—

Dividend streakyrs

Op margin range%

32–36

$1 testx

—

Incr. ROIC%

—

MSBIO, Inc. engages in the developing, manufacturing, and selling products that restores and treats damaged human tissues in South Korea. The company offers allograft tissue products, such as GenerFill H, MYBONE, MS Aminion, and MYDERM.

Growth vs revenue

Latest

Trend

2Y CAGR

Rel growth

Revenue

₩23.79B

26.68%

1.00×

Cost of revenue

₩8.001B

17.51%

0.86×

Operating expenses

₩7.228B

28.87%

1.03×

Asset mix

Trend

Other

67.50%

Cash and investments

31.30%

Goodwill & intangibles

1.20%

Reinvestment returns

3Y median

Trend

Reinvestment rate

0.08%

Return on capital

38.00%

Spread over hurdle

31.35%